Considerations for Switching Systemic Agents in Atopic Dermatitis

Panelists discuss the prevalence of treatment-refractory moderate to severe atopic dermatitis, noting factors such as intolerance or inability to use high-potency topical agents as common reasons for treatment failure, and emphasize the importance of considering alternative agents or switching treatments when necessary, particularly in pediatric patients, with biologics and Janus kinase (JAK) inhibitors being key options as evidenced by studies such as Blauvelt 2023, Keow & Abu-Hilal 2024 , and JADE EXTEND.